Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, discusses microstructure intelligence in more detail in part 2 of this preview of the company’s keynote presentation at AAPS PharmSci 360.
News|Articles|January 28, 2022
- Pharmaceutical Technology's In the Lab eNewsletter, February 2022
- Volume 17
- Issue 2
IonSense’s DART-MS Technology Selected for New Drug Screening Program
Author(s)Pharmaceutical Technology Editors
IonSense’s DART-MS technology offers rapid drug analysis without the need for sample preparation.
Advertisement
IonSense, a US-based provider of direct analysis in real time mass spectrometry (DART) for rapid mass spectral analysis, has been selected to have its DART-MS technology used as part of the “Rapid Analysis of Drugs” program, a new drug screening program that is being piloted in five states across the United States. The pilot program is being used to test drugs and drug paraphernalia by utilizing the high-accuracy, fast detection mass spectrometry capability enabled by IonSense’s DART technology to identify the contents of drugs within minutes at the point of need.
The screening program was first launched by the Governor of Maryland, in conjunction with the Maryland State Police, Maryland Department of Health, and National Institute of Standards and Technology in December 2021, to identify illicit drugs and counter recent increase in overdose deaths. The program has also been adopted by four further states with Alabama, Virginia, Texas and Washington DC implementing the scheme and more states expected to follow in quick succession, according to a Jan. 13, 2022 press release.
DART is an ionization source that uniquely analyzes a variety of particles (including solids, liquids and gases) without the need for sample preparation, which removes a major time-consuming step, allowing users to rapidly identify samples, including many that do not ionize well, at the point of need.
Source:
Articles in this issue
over 4 years ago
Multispecific Analyses of Biologics Pose Multiple Challengesover 4 years ago
Analytical Skills Are Needed in Biologics Testingover 4 years ago
Predicting Toxicity in Drug Developmentover 4 years ago
Texcell North America Builds New Laboratory Facilityover 4 years ago
Refeyn Announces SamuxMP for AAV Characterizationover 4 years ago
Fujifilm Grows Lab Space at North Carolina FacilityAdvertisement
Related to this article
In part 1 of this 2-part preview of AAPS PharmSci 360’s keynote on predictive drug development, Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, explains microstructure intelligence and how it can enhance how drug developers understand the dosage form.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Advertisement
Advertisement